PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 16, 2019Acta cardiologica. Supplementum

Looking back on 15 years of ultrasound-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does ultrasound-guided alcohol septal ablation improve symptoms and reduce LVOT obstruction in patients with HOCM refractory to medical therapy?

Population

26 patients with hypertrophic obstructive cardiomyopathy with persistent dyspnoea, angina or syncope despite…

Design

Case_series

Follow-up

7.2 ± 4.7 years

Key result

Ultrasound-guided alcohol septal ablation resulted in sustained clinical improvement in 86% of HOCM patients, reducing resting LVOT gradient to 21 ± 15 mmHg over a 7.2-year follow-up.

Authors

IVIlse VermaeteKDKarl DujardinFSFrancis Stammen

Discussion

Loading...

Member takes

Overview

May support use in refractory HOCM; hypothesis-generating and requires prospective trials before practice change.

Study Design

Type

Observational (n=26)

Structured PICO

Does ultrasound-guided alcohol septal ablation improve symptoms and reduce LVOT obstruction in patients with HOCM refractory to medical therapy?

P
Population
26 HOCM patients with persistent dyspnoea, angina or syncope despite optimal medical treatment, followed for an average of 7.2 years.
E
Exposure
Ultrasound-guided alcohol septal ablation (ASA)
O
Outcome
Clinical improvement, reduction of septal wall thickness, and resting LVOT gradient

Ultrasound-guided alcohol septal ablation provides sustained clinical improvement and reduction in LVOT gradients in selected patients with medically refractory HOCM.

Cite This Study

Vermaete et al. (2019) conducted an observational in hypertrophic obstructive cardiomyopathy (HOCM) (n=26). ultrasound-guided alcohol septal ablation was evaluated on sustained clinical improvement. Ultrasound-guided alcohol septal ablation resulted in sustained clinical improvement in 86% of HOCM patients, reducing resting LVOT gradient to 21 ± 15 mmHg over a 7.2-year follow-up.

synapsesocial.com/papers/6a2011ac9d62e9997c04bf12https://doi.org/10.1080/00015385.2019.1626550
View Full Paper
Ask AI
Bookmark
Share